1.15 USD
↗ 0.03 (2.68%)AT CLOSE (03:59 PM EDT)
Geron Corp
GERNNASDAQ • USD
1.15
↗ 0.00 (0.00%)
POST MARKET (AS OF 06:18 PM EDT)
Post Market
AS OF 06:18 PM EDT
1.15
↗ 0.00 (0.00%)
Market: OPEN
Geron Corp (GERN) trades at $1.15 per share. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place GERN at a fair price relative to peers.
Technical & fundamental data as of Oct 26, 2026.
Open?$1.12
High?$1.17
Low?$1.10
Prev. Close?$1.12
Volume?11.1M
Avg. Volume?8.7M
VWAP?$1.15
Rel. Volume?1.27x
Bid / Ask
Bid?$0.99 × 100
Ask?$1.32 × 100
Spread?$0.33
Midpoint?$1.15
Valuation & Ratios
Market Cap?719.6M
Shares Out?642.5M
Float?626.7M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?3.29
EPS?-$0.11
Dividend?0.00%
Ex-Dividend?N/A
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Themes
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?20
Short Sent.?54
Piotroski F-Score?2/9Weak
Altman Z-Score?-2.60Distress
Confidence?61%Moderate
Short InterestHigh
Short % of Float?11.90%High
Short Interest?74.6M
Days to Cover?9.9
Free Float626.7M
Avg Daily Volume7.6M
Settlement Date2026-10-15
Financial Health
Current Ratio?6.92Strong
Quick Ratio?5.16Strong
Cash Ratio?0.89Adequate
Debt/Equity?1.14Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score75/100
P/E?N/A▾
P/B?3.29FAIR▾
Peers100
S&P51
P/S?3.52FAIR▾
Peers100
S&P44
P/FCF?N/A▾
EV/EBITDA?-26.1CHEAP▾
Peers100
S&P97
EV/Sales?4.43FAIR▾
Peers100
S&P41
Returns & Efficiency
ROE?-30.9%WEAK▾
Peers50
S&P6
ROA?-13.0%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-114762000
Enterprise Value?$906.7M
Fundamentals ratios updated end of day